FAQs

Show all

Verona Pharma’s American Depository Shares (ADSs) are listed on The NASDAQ Global Market under the symbol “VRNA”.  The Company’s ordinary shares trade on AIM, a market of the London Stock Exchange, under the symbol “VRP” 
The Company’s initial public offering of its American Depository Shares (ADSs) on the NASDAQ Global Market occurred on 27 April, 2017.  The ordinary shares commenced trading on the AIM, a market of the London Stock Exchange on 18 September, 2006.
Verona Pharma is headquartered in London, England.
Verona Pharma was founded in February 2005.
Verona Pharma is incorporated under the laws of England and Wales.
You can view our management team by visiting Our Team on our website. 
Verona Pharma’s fiscal year end is December 31.  
For Verona Pharma’s American Depository Shares (ADSs) listed on The NASDAQ Global Market, the CUSIP number is 925050106 and ISIN number is US9250501064.  For the ordinary shares traded on AIM, a market of the London Stock Exchange, the ISIN number is GB00BYW2KH80.
Shares can be purchased through a stockbroker of your choice. 
Currently, Verona Pharma does not pay a dividend.
Currently, Verona Pharma does not offer a direct stock repurchase plan. 
Verona Pharma’s auditor is PricewaterhouseCoopers LLP. 
The transfer agent for the American Depository Shares (ADSs) listed on The NASDAQ Global Market, is Citigroup. You can contact them as follows:

Citigroup
Depositary Services
388 Greenwich Street
New York, New York 10013

The transfer agent for the ordinary shares traded on AIM, a market of the London Stock Exchange, is Computershare. You can contact them as follows:

Computershare Investor Services plc
PO Box 82, The Pavilions 
Bridgewater Road
Bristol BS99 7NH UK
 

Please contact our transfer agent, the details of which are provided above. There is a fee involved for replacing lost certificates. 
You must send both your old and new addresses to our transfer agent, the details of which are provided above.  Each stockholder in question must sign the request for an address change.
Verona Pharma’s legal counsel is Latham & Watkins LLP. 
You can view information on our platform and programs by visiting the Product Pipeline section of our website. 
You can view our recent press releases by visiting the News and Media section of our website.
Quarterly & Annual Reports and other investor materials are available under Reports of the Download Centre section of our corporate website.  Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.
More information can be found on the Verona Pharma website and the SEC website.
For investor relations inquiries, you may submit inquiries by contacting Stephanie Carrington at ICR Inc. at +1-646-277-1282 or stephanie.carrington@icrinc.com in the US, or Simon Conway at FTI Consulting at +44 (0)20 3727 1000 or veronapharma@fticonsulting.com in the UK.